Amendment No. 3 to Schedule 13D for LAVA Therapeutics N.V.

This Amendment No. 3 to Schedule 13D, filed by Cooperatieve Gilde Healthcare IV U.A., reports the sale of 1,933,030 common shares of LAVA Therapeutics N.V. between October 20, 2025, and October 21, 2025. The sales were conducted in open market transactions, with Gilde Healthcare selling 1,000,000 shares at a weighted average price of $1.4647 per share on October 20, 2025, and 933,030 shares at a weighted average price of $1.4664 per share on October 21, 2025. As a result of these transactions, the reporting persons ceased to beneficially own more than 5% of the issuer's outstanding common shares. The amendment also updates the beneficial ownership of the reporting persons, who now hold 1,014,751 common shares, representing approximately 3.9% of the outstanding shares as of August 8, 2025.